Genmab AS (CHIX:GMABC) Cash Flow from Operations: kr5,679 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GMABC Genmab AS CHIX:GMABC
97 GF Score
Price kr2,117.00
GF Value kr2,215.87
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Genmab AS Cash Flow from Operations?

Genmab AS CHIX:GMABC 97 Cash Flow from Operations is kr5,679 Mil as of Jun. 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 97/100 and a GF Value™ of kr2,215.87 (Fairly Valued). The stock has 7 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2026, Genmab AS's Net Income From Continuing Operations was kr1,915 Mil. Its Depreciation, Depletion and Amortization was kr169 Mil. Its Change In Working Capital was kr-1,733 Mil. Its cash flow from deferred tax was kr0 Mil. Its Cash from Discontinued Operating Activities was kr0 Mil. Its Asset Impairment Charge was kr6 Mil. Its Stock Based Compensation was kr240 Mil. And its Cash Flow from Others was kr-266 Mil. In all, Genmab AS's Cash Flow from Operations for the three months ended in Jun. 2026 was kr331 Mil.


Genmab AS  (CHIX:GMABc) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Genmab AS's net income from continuing operations for the three months ended in Jun. 2026 was kr1,915 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Genmab AS's depreciation, depletion and amortization for the three months ended in Jun. 2026 was kr169 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Genmab AS's change in working capital for the three months ended in Jun. 2026 was kr-1,733 Mil. It means Genmab AS's working capital declined by kr1,733 Mil from Mar. 2026 to Jun. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Genmab AS's cash flow from deferred tax for the three months ended in Jun. 2026 was kr0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Genmab AS's cash from discontinued operating Activities for the three months ended in Jun. 2026 was kr0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Genmab AS's asset impairment charge for the three months ended in Jun. 2026 was kr6 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Genmab AS's stock based compensation for the three months ended in Jun. 2026 was kr240 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Genmab AS's cash flow from others for the three months ended in Jun. 2026 was kr-266 Mil.


Genmab AS Cash Flow from Operations Related Terms


Genmab AS Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cash Flow from Operations Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,232.16 3,954.23 7,320.07 8,019.49 7,564.78

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 401.02 3,408.42 1,919.90 19.40 331.01
CHIX:GMABC
97GF Score
Genmab AS CHIX:GMABC
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Genmab AS's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:

Genmab AS's Cash Flow from Operations for the quarter that ended in Jun. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5,679 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of kr5,679 Mil mean?
Genmab AS (CHIX:GMABC) has a Cash Flow from Operations of kr5,679 Mil as of Jun. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Genmab AS and its competitors.
Is Genmab AS's Cash Flow from Operations too high?
Genmab AS's current Cash Flow from Operations is kr5,679 Mil. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cash Flow from Operations compare to VRTX and REGN?
Genmab AS's Cash Flow from Operations of kr5,679 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Genmab AS and its competitors. Genmab AS's current Cash Flow from Operations is kr5,679 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,215.87, compared to a current price of kr2,117.00 — trading 4.5% below its estimated fair value. The current Cash Flow from Operations is kr5,679 Mil. Genmab AS's overall GF Score™ is 97/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Cash Flow from Operations is kr5,679 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr2,117.00 is trading 4.5% below its estimated GF Value™ of kr2,215.87. GuruFocus considers Genmab AS to be Fairly Valued.

Key valuation signals for CHIX:GMABC:

  • Cash Flow from Operations: kr5,679 Mil
  • GF Value™: kr2,215.87 vs. price of kr2,117.00 (4.5% below fair value)
  • GF Score™: 97/100 with 7 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score

Get the complete analysis for CHIX:GMABC

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2,117.00
Price
kr2,215.87
GF Value